Innovation in pharmaceutical and health biotechnology industries: challenges for a virtuous agenda

被引:10
|
作者
Vargas, Marco [1 ,2 ]
Grabois Gadelha, Carlos Augusto [2 ,3 ,4 ]
Costa, Lais Silveira [2 ]
Maldonado, Jose [2 ,4 ]
机构
[1] Univ Fed Fluminense, Dept Econ, Fac Econ, Niteroi, RJ, Brazil
[2] Fundacao Oswaldo Cruz Fiocruz, Grp Pesquisa Inovacao Saude, Escola Nacl Saude Publ Sergio Arouca ENSP, Rio De Janeiro, RJ, Brazil
[3] Minist Saude, Secretaria Ciencia Tecnol & Insumos Estrateg, Brasilia, DF, Brazil
[4] ENSP Fiocruz, CT&I Saude, Rio De Janeiro, RJ, Brazil
来源
REVISTA DE SAUDE PUBLICA | 2012年 / 46卷
关键词
Biotechnology; economics; Chemical Industry; Technological Development; policies; National Science; Technology and Innovation Policy;
D O I
10.1590/S0034-89102012000700006
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Pharmaceutical and biotechnology industries comprise a major production subsystem of the health industrial complex in Brazil. It stands out for both its economic importance and its prominent role in developing new technologies in strategic areas. Strengthening the local production of generic drugs in the last decade has significantly increased the number of Brazilian companies in the local pharmaceutical market and has been an important turning point for this industry's growth. However, there remain major structural bottlenecks both in terms of production and continuous innovation. These bottlenecks reveal the high vulnerability of the Brazilian National Health System and point to the need of public policies that promote strengthening the production base and innovation in the pharmaceutical industry and that at the same time meet health-related social demands in health in Brazil.
引用
收藏
页码:37 / 40
页数:4
相关论文
共 50 条